Mark A. Goldsmith has demonstrated a pronounced selling bias in his recent insider transactions, primarily involving shares of Revolution Medicines (RVMD). Over the past 18 months, Goldsmith has executed 18 sales totaling approximately $17.01 million, with no recent purchases recorded. The bulk of this activity occurred in concentrated bursts, including a $1.28 million sale on March 17, 2026, and a series of disposals on March 2, 2026, ranging from $9,831 to $2.17 million. Earlier transactions in late 2025 were similarly weighted toward selling, with notable dispositions of $4.5 million and $1.41 million in November of that year.
Goldsmith’s trading history reveals a clear pattern of reducing his position in RVMD, with sales often accompanied by smaller option-related transactions marked as "M" (derivative) or "A" (award) codes. The absence of any buys during this period—contrasted with $631,102 in total historical purchases—suggests a sustained divestment strategy. The transactions, particularly the multimillion-dollar sales in late 2025 and early 2026, indicate a methodical unwinding of holdings rather than sporadic adjustments. While the filings do not disclose the rationale, the scale and consistency of the sales underscore a deliberate shift away from RVMD exposure.
AI-assisted summary